Verition Fund Management’s Pacira BioSciences PCRX Stock Holding History

Verition Fund Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$297K	Sell	11,692 -18,227	-61%	-$431K	﹤0.01%	1758
2026 Q1	$676K	Sell	29,919 -55,470	-65%	-$1.23M	﹤0.01%	1482
2025 Q4	$2.21M	Buy	+85,389	New	+$2.03M	0.01%	1514
2025 Q3	–	Sell	-27,662	Closed	-$661K	–	3948
2025 Q2	$661K	Buy	27,662 +8,345	+43%	+$210K	﹤0.01%	2765
2025 Q1	$480K	Sell	19,317 -6,748	-26%	-$162K	﹤0.01%	2609
2024 Q4	$491K	Sell	26,065 -6,723	-21%	-$118K	﹤0.01%	2498
2024 Q3	$493K	Buy	+32,788	New	+$561K	﹤0.01%	2332
2024 Q1	–	Sell	-10,254	Closed	-$346K	–	2926
2023 Q4	$346K	Sell	10,254 -1,220	-11%	-$35.7K	﹤0.01%	1722
2023 Q3	$352K	Buy	+11,474	New	+$414K	﹤0.01%	1636
2023 Q1	–	Sell	-8,433	Closed	-$326K	–	2463
2022 Q4	$326K	Buy	8,433 +4,315	+105%	+$210K	0.01%	1457
2022 Q3	$219K	Buy	+4,118	New	+$229K	﹤0.01%	2440
2022 Q2	–	Sell	-49,287	Closed	-$3.76M	–	2886
2022 Q1	$3.76M	Buy	49,287 +16,954	+52%	+$1.13M	0.05%	536
2021 Q4	$1.95M	Buy	+32,333	New	+$1.78M	0.01%	905
2017 Q2	–	Sell	-6,743	Closed	-$307K	–	1204
2017 Q1	$307K	Buy	+6,743	New	+$291K	0.03%	836

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verition Fund Management's PCRX Position: Q2 2026 in Review

Verition Fund Management reduced its Pacira BioSciences (PCRX) stake by 61% in Q2 2026, selling an estimated $431K and leaving 11,692 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #1758.

Verition Fund Management first reported a position in PCRX in Q1 2017 and has held it in 14 quarters since. The position peaked at $3.76M in Q1 2022. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Verition Fund Management held 11,692 shares of Pacira BioSciences worth $297K as of Q2 2026.
Verition Fund Management sold 18,227 Pacira BioSciences shares in Q2 2026, an estimated $431K.
Pacira BioSciences made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1758 holding.
Verition Fund Management first reported a position in Pacira BioSciences in Q1 2017 and has held it in 14 quarters since.
Verition Fund Management's Pacira BioSciences position peaked at $3.76M in Q1 2022.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.